Trial Profile

A phase 3 Clinical Trials of Nelonemdaz in severe Ischaemic-stroke

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelonemdaz (Primary)
Indications Ischaemic stroke
Focus Registrational; Therapeutic Use

Most Recent Events

13 Aug 2025 New trial record
24 Jul 2025 According to the GNT Pharma Media Release, company announced its IND Application to commence Global Phase 3 Clinical Trials of its lead drug Nelonemdaz, has been approved by MFDS - South Korea's regulatory body. and will be conducted across more than 20 world-leading stroke centers in Korea, USA, and Australia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com